The analysis of myotonia congenita mutations discloses functional clusters of amino acids within the CBS2 domain and the C-terminal peptide of the ClC-1 channel.

Maria Teresa Dotti, Jean-François Desaphy, Paola Imbrici, Diana Conte, Maria Rosaria Carratù, Michael G Hanna, Emma Matthews, Mauro Lo Monaco, Giovanni Meola, Rosanna Cardani, Concetta Altamura, Tiziana Mongini, Liliana Vercelli, Luisa Politano, Roberta Petillo, Paola D'Ambrosio, Giacomo P Comi, Gianna Ulzi, Dalila Sahbani, Sabrina Lucchiari

Journal: Human mutation 2019;39(9):1273-1283

PMID: 29935101

Abstract

Myotonia congenita (MC) is a skeletal-muscle hyperexcitability disorder caused by loss-of-function mutations in the ClC-1 chloride channel. Mutations are scattered over the entire sequence of the channel protein, with more than 30 mutations located in the poorly characterized cytosolic C-terminal domain. In this study, we characterized, through patch clamp, seven ClC-1 mutations identified in patients affected by MC of various severities and located in the C-terminal region. The p.Val829Met, p.Thr832Ile, p.Val851Met, p.Gly859Val, and p.Leu861Pro mutations reside in the CBS2 domain, while p.Pro883Thr and p.Val947Glu are in the C-terminal peptide. We showed that the functional properties of mutant channels correlated with the clinical phenotypes of affected individuals. In addition, we defined clusters of ClC-1 mutations within CBS2 and C-terminal peptide subdomains that share the same functional defect: mutations between 829 and 835 residues and in residue 883 induced an alteration of voltage dependence, mutations between 851 and 859 residues, and in residue 947 induced a reduction of chloride currents, whereas mutations on 861 residue showed no obvious change in ClC-1 function. This study improves our understanding of the mechanisms underlying MC, sheds light on the role of the C-terminal region in ClC-1 function, and provides information to develop new antimyotonic drugs.

© 2018 Wiley Periodicals, Inc.

Address: Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Bari, Italy.; Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milan, Italy.; Neurology Unit, IRCCS Fondazione Ca' Grande Ospedale Maggiore Policlinico, Milan, Italy.; Cardiomyology and Medical Genetics, Department of Experimental Medicine, University of Campania, Naples, Italy.; Neuromuscular Unit, Department of Neurosciences, Hospital Città della Salute e della Scienza of Torino, University of Torino, Turin, Italy.; Unit of Neurology and Neurometabolic Disorders, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.; Laboratory of Muscle Histopathology and Molecular Biology, IRCCS Policlinico San Donato, Milan, Italy.; Department of Biomedical Sciences for Health, University of Milan, IRCCS Policlinico San Donato, Milan, Italy.; Institute of Neurology, Catholic University of Sacred Heart, Polyclinic Gemelli, Rome, Italy.; MiA Onlus ("Miotonici in Associazione"), Portici, Italy.; MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.; Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Polyclinic, Bari, Italy.

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.